Gilead's new twice-yearly HIV preventative shot is hailed as a groundbreaking advancement in the fight against AIDS, showing 100% effectiveness in trials with women and impressively high efficacy among men.
UNAIDS noted that the breakthrough drug, lenacapavir, represents a vital opportunity to control HIV, emphasizing that its availability in high-risk areas is crucial to ending the epidemic.
Winnie Byanyima commended Gilead's effort but emphasized that excluding Latin America from access to the generic version of lenacapavir could hinder global HIV prevention efforts, despite lower rates.
Various prevention methods exist, but the twice-yearly injection could significantly aid marginalized communities who often feel apprehensive about seeking healthcare, presenting a more approachable solution.
Collection
[
|
...
]